tremelimumab

FDA Drug Profile — IMJUDO

tremelimumab is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including IMJUDO. Available dosage form: injection, solution.

Drug details

Generic Name
tremelimumab
Brand Names
IMJUDO
Application Number
BLA761289
Sponsor
AstraZeneca Pharmaceuticals LP
NDC Codes
4
Dosage Forms
INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients
TREMELIMUMAB

Indications and Usage

1 INDICATIONS AND USAGE IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) 1.1 Hepatocellular Carcinoma IMJUDO, in combination with durvalumab, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.2 Non-Small Cell Lung Cancer (NSCLC) IMJUDO, in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.